We therefore carried out a preliminary investigation to evaluate whether the PTTG1 protein was present also in plasma of melanoma patients and whether changes in PTTG1 levels, possibly related to clinical response, could occur during therapy with BRAFi (dabrafenib or vemurafenib) or the combination of dabrafenib plus trametinib. The gene discussed is PTTG1; the disease is melanoma.